Proteomics in Diagnostic Evaluation and Treatment of Breast Cancer: A Scoping Review.

IF 3 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES
Menelaos Zafrakas, Ioannis Gavalas, Panayiota Papasozomenou, Christos Emmanouilides, Maria Chatzidimitriou
{"title":"Proteomics in Diagnostic Evaluation and Treatment of Breast Cancer: A Scoping Review.","authors":"Menelaos Zafrakas, Ioannis Gavalas, Panayiota Papasozomenou, Christos Emmanouilides, Maria Chatzidimitriou","doi":"10.3390/jpm15050177","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objectives:</b> The aim of this scoping review was to delineate the current role and possible applications of proteomics in personalized breast cancer diagnostic evaluation and treatment. <b>Methods:</b> A comprehensive search in PubMed/MEDLINE and Scopus/EMBASE was conducted, according to the PRISMA-ScR guidelines. Inclusion criteria: proteomic studies of specimens from breast cancer patients, clinically relevant studies and clinical studies. Exclusion criteria: in silico, in vitro and studies in animal models, review articles, case reports, case series, comments, editorials, and articles in language other than English. The study protocol was registered in the Open Science Framework. <b>Results:</b> In total, 1093 records were identified, 170 papers were retrieved and 140 studies were selected for data extraction. Data analysis and synthesis of evidence showed that most proteomic analyses were conducted in breast tumor specimens (n = 77), followed by blood samples (n = 48), and less frequently in other biologic material taken from breast cancer patients (n = 19). The most commonly used methods were liquid chromatography-tandem mass spectrometry (LC-MS/MS), followed by Matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF), Surface-Enhanced Laser Desorption/Ionization Time-of-Flight (SELDI-TOF) and Reverse Phase Protein Arrays (RPPA). <b>Conclusions:</b> The present review provides a thorough map of the published literature reporting clinically relevant results yielded from proteomic studies in various biological samples from different subgroups of breast cancer patients. This analysis shows that, although proteomic methods are not currently used in everyday practice to guide clinical decision-making, nevertheless numerous proteins identified by proteomics could be used as biomarkers for personalized diagnostic evaluation and treatment of breast cancer patients.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 5","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12113354/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jpm15050177","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: The aim of this scoping review was to delineate the current role and possible applications of proteomics in personalized breast cancer diagnostic evaluation and treatment. Methods: A comprehensive search in PubMed/MEDLINE and Scopus/EMBASE was conducted, according to the PRISMA-ScR guidelines. Inclusion criteria: proteomic studies of specimens from breast cancer patients, clinically relevant studies and clinical studies. Exclusion criteria: in silico, in vitro and studies in animal models, review articles, case reports, case series, comments, editorials, and articles in language other than English. The study protocol was registered in the Open Science Framework. Results: In total, 1093 records were identified, 170 papers were retrieved and 140 studies were selected for data extraction. Data analysis and synthesis of evidence showed that most proteomic analyses were conducted in breast tumor specimens (n = 77), followed by blood samples (n = 48), and less frequently in other biologic material taken from breast cancer patients (n = 19). The most commonly used methods were liquid chromatography-tandem mass spectrometry (LC-MS/MS), followed by Matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF), Surface-Enhanced Laser Desorption/Ionization Time-of-Flight (SELDI-TOF) and Reverse Phase Protein Arrays (RPPA). Conclusions: The present review provides a thorough map of the published literature reporting clinically relevant results yielded from proteomic studies in various biological samples from different subgroups of breast cancer patients. This analysis shows that, although proteomic methods are not currently used in everyday practice to guide clinical decision-making, nevertheless numerous proteins identified by proteomics could be used as biomarkers for personalized diagnostic evaluation and treatment of breast cancer patients.

蛋白质组学在乳腺癌诊断评估和治疗中的应用:综述。
目的:本综述的目的是描述蛋白质组学在个性化乳腺癌诊断评估和治疗中的作用和可能的应用。方法:根据PRISMA-ScR指南,在PubMed/MEDLINE和Scopus/EMBASE中进行综合检索。纳入标准:乳腺癌患者标本的蛋白质组学研究、临床相关研究和临床研究。排除标准:计算机、体外和动物模型研究、综述文章、病例报告、病例系列、评论、社论和非英语语言的文章。研究方案已在开放科学框架中注册。结果:共检索到1093条记录,检索到170篇论文,筛选出140篇研究进行数据提取。数据分析和证据综合表明,大多数蛋白质组学分析是在乳腺肿瘤标本(n = 77)中进行的,其次是血液样本(n = 48),较少用于从乳腺癌患者身上采集的其他生物材料(n = 19)。最常用的方法是液相色谱-串联质谱法(LC-MS/MS),其次是基质辅助激光解吸/电离飞行时间(MALDI-TOF)、表面增强激光解吸/电离飞行时间(SELDI-TOF)和反相蛋白质阵列(RPPA)。结论:本综述提供了一个完整的已发表文献图谱,这些文献报告了来自乳腺癌患者不同亚组的各种生物样本的蛋白质组学研究产生的临床相关结果。这一分析表明,尽管蛋白质组学方法目前还没有在日常实践中用于指导临床决策,但通过蛋白质组学鉴定的许多蛋白质可以作为生物标志物用于乳腺癌患者的个性化诊断评估和治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Personalized Medicine
Journal of Personalized Medicine Medicine-Medicine (miscellaneous)
CiteScore
4.10
自引率
0.00%
发文量
1878
审稿时长
11 weeks
期刊介绍: Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., pharmacogenomics/proteomics, systems biology). JPM recognizes that personalized medicine—the assessment of genetic, environmental and host factors that cause variability of individuals—is a challenging, transdisciplinary topic that requires discussions from a range of experts. For a comprehensive perspective of personalized medicine, JPM aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects. We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信